As seen in Oncologist Daily, ASCO 2025 Edition 

The pace of progress in oncology is both exhilarating and overwhelming. New clinical trials, biomarkers, FDA approvals, and updated guidelines appear almost daily, creating a deluge of information that even the most diligent oncologists struggle to absorb. For Anna Forsythe, who had lost two good friends to cancer — and who is trying to help a third with a difficult diagnosis — this was more than just a challenge. It was a call to action. 

As the founder of Oncoscope AI, Anna has set out to build what she calls “a GPS for oncology.” Much like a car navigation system that recalculates routes in real time based on constantly changing traffic patterns, Oncoscope AI continuously updates to reflect the latest evidence — synthesizing and collating research data, treatment guidelines and regulatory approvals into a single, streamlined view designed for oncologists to use in real time at the point of care. 

“Oncoscope doesn’t replace the physician’s judgment,” Forsythe explains. “It augments it — giving clinicians a clear, current, and unbiased and easy to use view of what’s changing in real time, so they can spend less time digging through papers and more time with their patients.” 

This balance of innovation and practicality reflects Anna’s own background. A clinically trained Doctor of Pharmacy, she holds a Master’s Degree in Health Economics and Policy from the University of Birmingham (UK) and an MBA from Columbia University. Her career spans both the clinical and strategic sides of the pharmaceutical industry — with leadership in both oncology and non-oncology roles roles in global value and access at Eisai Co., and earlier positions at Novartis and Bayer in clinical research and health economics. 

She’s no stranger to entrepreneurship either. Anna previously co-founded Purple Squirrel Economics, a health economics consultancy that was acquired by Cytel, the Cambridge, Massachusetts-based statistical software developer and contract research organization, in 2020. Her work has appeared in leading journals and conference podiums alike, including a top-ranked JAMA Pediatrics article, which placed in the top 5 percent of all JAMA research outputs worldwide. 

But it’s Oncoscope that brings her experiences full circle — combining clinical insight, economic acumen, and a passion for scalable solutions that work in real-world oncology settings. As thousands of oncologists gather at ASCO 2025 to digest the latest data and translate it into better care, Oncoscope AI offers a timely reminder that innovation doesn’t have to be overwhelming — if it’s built from the ground up with the physician in mind.  

“We’re not a technology in search of an application — and we’re not at all suggesting that oncologists change how they practice,” says Forsythe.

“They are the experts. We are merely helping them by building a tool that fits seamlessly into their reality — one that helps them keep up with the latest information, and communicate the most up-to-date strategies clearly with patients. The goal is to help them stay focused on what matters most: delivering the best possible care.”

With Oncoscope AI, Anna Forsythe is leading a new kind of precision oncology — one where evidence and empathy meet at the bedside, powered by smart, real-time technology.